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Abstract
Synovial sarcomas are aggressive soft-tissue malignancies that express chromosomal 
translocation-generated fusion genes, SS18-SSX1 or SS18-SSX2 in most cases. Here, we report a 
mouse sarcoma model expressing SS18-SSX1, complementing our prior model expressing SS18-
SSX2. Exome sequencing identified no recurrent secondary mutations in tumors of either 
genotype. Most of the few mutations identified in single tumors were present in genes that were 
minimally or not expressed in any of the tumors. Chromosome 6, either entirely or around the 
fusion gene expression locus, demonstrated a copy number gain in a majority of tumors of both 
genotypes. Thus, by fusion oncogene coding sequence alone, SS18-SSX1 and SS18-SSX2 can 
each drive comparable synovial sarcomagenesis, independent from other genetic drivers. SS18-
SSX1 and SS18-SSX2 tumor transcriptomes demonstrated very few consistent differences overall. 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
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In direct tumorigenesis comparisons, SS18-SSX2 was slightly more sarcomagenic than SS18-
SSX1, but equivalent in its generation of biphasic histologic features. Meta-analysis of human 
synovial sarcoma patient series identified two tumor-gentoype-phenotype correlations that were 
not modeled by the mice, namely a scarcity of male hosts and biphasic histologic features among 
SS18-SSX2 tumors. Re-analysis of human SS18-SSX1 and SS18-SSX2 tumor transcriptomes 
demonstrated very few consistent differences, but highlighted increased native SSX2 expression in 
SS18-SSX1 tumors. This suggests that the translocated locus may drive genotype-phenotype 
differences more than the coding sequence of the fusion gene created. Two possible roles for 
native SSX2 in synovial sarcomagenesis are explored. Thus even specific partial failures of mouse 
genetic modeling can be instructive to human tumor biology.
Keywords
genetic mouse model; RNAseq; transcriptome; exome sequencing
Introduction
Synovial sarcoma is the most common soft-tissue sarcoma in young adults and adolescents1. 
Although more responsive to cytotoxic chemotherapy than some other sarcomas, synovial 
sarcoma proves to be ultimately resistant to most therapies and is usually fatal after 
metastasis. Synovial sarcoma cells have been shown consistently to bear a balanced t(X;18) 
chromosomal translocation2 that generates a fusion between SS18 (formerly called SYT) 
and an SSX gene3.
Almost the entire SS18 coding sequence is included in each fusion, while only the final 78 
amino acids of SSX1 or SSX2 are included4,5 By sequence analysis, members of the SSX 
gene family are projected to be transcriptional repressors (Supplementary Fig. 1); their 
expression is limited to the testis and a few cancers; and little more is known about them 
beyond their involvement in synovial sarcoma fusions6–8. SS18 has been shown to be a 
member of the mammalian SWI/SNF complex9,10.
Epigenetic mechanisms have been described wherein SS18-SSX fusion oncoproteins serve 
as master regulators of transcription in synovial sarcoma cell lines10,11. These mechanisms 
led to the hypothesis that SS18-SSX fusion genes were singular driving genetic events in 
synovial sarcomagenesis12. This hypothesis has been supported by limited comparative 
genomic hybridization and sequencing data that identified few copy number variations and 
mutations in most synovial sarcomas13–15.
SS18-SSX2 expression in certain cell lineages proved to be sufficient to drive synovial 
sarcomagenesis in the mouse at 100 percent penetrance16,17. This was initially accepted as 
circumstantial proof that few or no other genetic changes were necessary for transformation. 
However, direct comparisons with two other sarcomagenic fusion oncogenes, EWSR1-ATF1 
and ASPSCR1-TFE3 (related to clear cell and alveolar soft part sarcoma, respectively) 
demonstrated that SS18-SSX2 generated fewer sarcomas at longer latencies18,19. This 
suggested that SS18-SSX2-driven sarcomagenesis may require some secondary genetic hit 
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or that the fusion itself was simply less oncogenic. This redirected attention toward SS18-
SSX1.
Early clinical series comparing SS18-SSX1 to SS18-SSX2 found the former to be more 
common and to associate with higher stage at presentation and worse prognosis20–24. Some 
subsequent series contradict this claim and a recent meta-analysis found no strong statistical 
evidence for it25, but the possibility of differential sarcomagenic potential was directly 
testable in the mouse.
Results
Comparable conditional mouse alleles of SS18-SSX1 and SS18-SSX2 expression
To investigate its oncogenic potential, we generated a mouse allele that conditionally 
expressed the SS18-SSX1 cDNA from the Rosa26 locus (termed hSS1, Fig. 1a). Using 
identical primers to capture the full-length coding sequence and early 3’ untranslated region, 
this hSS1 allele matched the previously described allele for SS18-SSX2 (herein termed 
hSS2)16. Mouse embryonic fibroblasts (MEFs) isolated from each model and exposed in 
culture to TATCre expressed their respective fusion genes (Fig. 1b) and underwent apoptosis 
(Fig. 1c). Similarly, both hSS1 and hSS2 disrupted early embryogenesis following 
expression induced by Hprt-Cre (Fig. 1d). Thus, hSS1 and hSS2 were similarly conditional 
and toxic to cells in most contexts.
SS18-SSX1 expression in mesenchymal progenitors drives synovial sarcomagenesis
Similar to prior reports with hSS216, mice were bred to activate hSS1 in the Myf5-Cre 
lineage. Tumors arose in full penetrance and expressed the fusion gene, as evidenced by 
fluorescence due to green fluorescent protein (GFP) expression from an internal ribosomal 
entry site on the targeted construct (Fig. 1e and 1a).
Synovial sarcomas are sub-classified histologically as monophasic synovial sarcoma (MSS), 
which lacks areas of epithelial differentiation, or biphasic synovial sarcoma (BSS), which 
contains both fibrous/mesenchymal and epithelial areas. Comparable both to human 
synovial sarcomas and to hSS2 mouse tumors, hSS1-driven tumors had both histologic types 
represented (Fig. 1f). As BSS histology indicates a fundamental reprogramming of germ-
layer cellular identities from mesenchymal origin to mucinous glandular structure formation, 
this is considered a diagnostic hallmark unique to synovial sarcoma. Finally, hSS1 tumors 
demonstrated the typical immunohistochemical staining with nuclear TLE1, cytoplasmic 
BCL2, and patchy epithelial membrane antigen and pan-cytokeratin (Fig. 1g). SS18-SSX1 is 
therefore also a fusion oncogene capable of driving synovial sarcomagenesis in the mouse.
Synovial sarcoma exomes have few somatic mutations, none recurrent by fusion type
In order to test the genetic independence of each fusion oncogene, we sequenced Myf5-Cre-
initiated tumor exomes for secondary mutations and compared them to germline control 
exomes. Few somatic mutations were identified (Fig. 2, Supplementary Tables 1 and 2). 
Targeted, deeper sequencing was used for validation of all mutations that had an allelic 
fraction of at least 10% in the tumor and no more than a single read in the germline control 
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tissue. Most identified mutations demonstrated variant allele fractions well below 40 
percent, which in light of the greater than 85 percent typical histologically-determined tumor 
cell density in the samples, suggests that the mutations were sub-clonal across the neoplasm 
and therefore had not contributed to initial malignant transformation.
Transcriptome sequencing demonstrated that most mutations also arose in genes that were 
minimally expressed in the mutated-allele-bearing tumor and minimally expressed in the 
other tumors that lacked the mutation. This supports their role as likely passenger mutations. 
Mutant transcript reads were only present as a large fraction of the reads that crossed the 
mutation site in genes that were minimally expressed overall. Notably, comparison of hSS1- 
and hSS2-induced tumors found a slight increase in the number of these passenger mutations 
in the former, which also developed and were harvested at an older age (Mean 262 versus 
168 days).
Mouse synovial sarcomas frequently amplify the fusion expression locus
Exome sequencing was also analyzed to determine copy number variation across the 
genome. The only repeated copy number variation was in mouse chromosome 6, which was 
amplified either completely as a trisomy or partially in 24 of the 29 tumors (Fig. 3a–b). The 
portion of chromosome 6 that was amplified always included the Rosa26 locus (Fig. 3a–b). 
PCR was used to test 8 samples with noted amplification and found that the targeted allele, 
from which the fusion was expressed, was amplified in every case relative to the wildtype 
allele (Fig. 3c). Comparative genomic hybridization was performed on an additional 11 
tumors of the hSS2 genotype, from 3 different mice, showing the same trisomy of 
chromosome 6 in 7 of the tumors (Supplementary Fig. 2), with no other consistent changes. 
Thus, the only genetic change that frequently contributes to mouse synovial sarcomagenesis 
is amplification of part or all of chromosome 6, consistently including the fusion gene 
expression locus.
Synovial sarcoma transcriptomes do not consistently differ by fusion genotype
In order to achieve a detailed molecular comparison of synovial sarcomas driven by each 
fusion genotype, we compared transcriptomes (RNAseq) for tumors of each genotype 
initiated by Myf5-Cre. Unsupervised hierarchical clustering yielded some intermingling of 
hSS1 and hSS2 tumors (Fig. 4a). Just over one thousand genes were differentially expressed 
between the two tumor genotypes at the p < 0.05 significance and 2-fold-change threshold 
(Supplementary Table 3). As a validation cohort, transcriptomes from 6 tumors initiated by 
TATCre injection into the hindlimb (3 of each fusion genotype) were also sequenced, with 
152 genes differentially expressed to the same degree (Fig. 4b, Supplementary Table 4). 
Only 18 genes were found to be shared as differentially expressed to the same degree and 
direction in both comparisons (Fig. 4c–e).
Comparable oncogenesis from SS18-SSX1 and SS18-SSX2 in the mouse
To directly compare their oncogenic potential, we developed comparative mouse cohorts of 
hSS1 and hSS2, each induced by Myf5-Cre, Rosa26-CreER, or hindlimb injection of the 
protein TATCre16,17,26. In each induction model, hSS1 expression resulted in slightly fewer, 
but comparably located tumors, at longer latencies (Fig. 5a–c).
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In the Myf5-Cre-induced mice, smaller tumors in both genotypes were MSS and rarely 
included epithelial areas. The Myf5-Cre;hSS2 mice more often had smaller, secondary 
tumors identified following euthanasia prompted by a larger tumor, rendering a non-
significant decrease in BSS prevalence in that group, overall (p=0.33, Fisher exact test; Fig.
5d). Analysis following stratification of tumors by size found equivalent prevalence of BSS 
histology in tumors >1 cm, irrespective of fusion genotype (Fig. 5d). The prevalence of BSS 
histology in tumors initiated by Rosa26-CreER and TATCre injection was also not 
significantly different (p=1.0 and p = 0.58, respectively; Fig. 5d).
Re-analysis of human synovial sarcomas identifies two genotype-phenotype correlations
Early human patient series correlated the SS18-SSX1 fusion genotype with worse prognosis. 
Some subsequent series have cast doubt on this. A meta-analysis found the impact to be 
subtle and not statistically significant. The prevalence of each fusion genotype has also 
varied somewhat between series.
To focus more clearly on differences associated with each fusion genotype, we retrieved raw 
data from 1181 patients in 17 of the largest clinical series of human synovial sarcomas in 
which the fusion type was identified by reverse transcriptase polymerase chain reaction (RT-
PCR). Gender data were available from 1036 patients in 12 of the studies. The typical 
sarcoma male to female ratio of approximately 1.2:1 was reflected among SS18-SSX1-
expressing tumors pooled from the available series (Table 1). A greater than 1.4-fold shift in 
gender prevalence was apparent in SS18-SSX2-expressing tumors (Table 1). There are 
significantly fewer males with SS18-SSX2 tumors than SS18-SSX1 tumors.
Some clinical series of human synovial sarcomas have reported more rare BSS histology in 
SS18-SSX2 tumors, compared to SS18-SSX1 tumors21,22,27. We compared the prevalence 
of BSS histology in each fusion genotype across the assembled 17 series. This demonstrated 
a statistically significant reduction in BSS histology cases in synovial sarcomas of the SS18-
SSX2 fusion genotype (p < 0.0001, Fisher exact test; Supplementary Table 5).
BSS histology in the SS18-SSX2 fusion genotype was also tested for gender association. 
The ratio of male to female biphasic tumors among those expressing SS18-SSX1 was 1.6-
fold higher than the ratio among tumors expressing SS18-SSX2 (Supplementary Table 6). 
Four series, including the largest, reported zero male patients with SS18-SSX2 BSSs.
These data pointed toward two genotype-phenotype relationships in human tumors that were 
not recapitulated in the mouse, reduced prevalence of male hosts to and BSS histology in 
SS18-SSX2 tumors.
Human SS18-SSX2 synovial sarcomas have reduced native SSX gene expression
To identify transcriptional differences between human tumors of each fusion genotype that 
were not represented in the mouse tumor genotype-expression profile comparisons, we re-
analyzed two patient series with reported microarray expression data. To avoid histologic 
bias, we limited initial comparisons to the pre-treatment MSS tumor samples in each cohort. 
Few genes had significant differential expression (with matched direction of change) 
between SS18-SSX1 and SS18-SSX2 tumors in both cohorts (Fig. 6a). When these were 
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cross-referenced to a third group of human samples (a relapsed tumors group from one of 
the two series), very few genes were significantly different in all three comparisons (Fig. 6a–
b). None of these correlated with the genes identified from the mouse comparisons. In 
particular, the SSX genes were prominently represented in the human comparisons, all more 
highly expressed in SS18-SSX1 tumors..
We designed RT-qPCR primer sets that targeted the 5’ end of either SSX1 or SSX2, portions 
not included in the respective fusion transcripts. This RT-qPCR analysis of expression in a 
panel of human synovial sarcomas demonstrated that tumors almost universally expressed 
native SSX2, but detectably expressed SSX1 in only about half of tumors (Fig. 6c). The only 
tumor with negligible native SSX2 expression was the single male case of an SS18-SSX2-
expressing MSS. The only tumor with higher SSX1 expression than SSX2 expression was in 
a female and was also driven by SS18-SSX2. SSX2 trended toward higher expression in 
SS18-SSX1 tumors (Fig. 6d).
This discrepancy in SSX gene expression between SS18-SSX1 and SS18-SSX2 human 
tumors was not recapitulated in mouse tumors. Expression of the known members of the 
homologous mouse Ssx gene family were not different between tumors of the two genotypes 
by RT-qPCR (Supplementary Figure 3a). In the mice, however, the fusion genes were 
expressed from cDNAs in the Rosa26 locus, which did not include structural rearrangements 
of the Ssx gene cluster on the X chromosome (Supplementary Figure 3b). Human synovial 
sarcomas therefore have two important differences between the translocations that generate 
the SS18-SSX1 and SS18-SSX2 fusion genotypes. First, the t(X;18) translocation in a 
human synovial sarcoma disrupts one allele of the involved, native SSX gene, whose 3' 
exons it repurposes in the fusion gene. This could be especially impactful in males, in which 
the fusion disrupts the only copy of the involved SSX gene. Second, because SSX2 is 
oriented away from all the other SSX genes, translocation to SSX2 does not bring any of the 
other native SSX genes into the area of influence of any regional chromatin effects of the 
high expression SS18 locus (Supplementary Figure 3c). This contrasts sharply to 
translocations in SSX1, which places most of the SSX genes, and SSX2 in particular, 
downstream and in close proximity to SS18.
Possible roles for native SSX2 in synovial sarcoma
The model systems for in vitro glandular differentiation of human synovial sarcoma cells are 
not developed yet and the mouse Ssx gene family homology to humans is not gene-specific 
enough to test BSS histology or basic tumorigenesis dependence on SSX2 in vivo. We are 
therefore left to only hypothesis-generating experiments to explain a role for the loss of 
native SSX2 in either reduced synovial sarcomas in males or reduced BSS histology.
Knock-down of SSX2 expression by small interfering RNA (siRNA) in human synovial 
sarcoma cell lines hampered proliferation compared to a non-target control siRNA (Fig. 7a–
e). Proliferation increased upon introduction of an SSX2 overexpression vector compared to 
control conditions (Fig. 7d–e). These data suggest that SSX2 may function as a contributing 
oncogene in synovial sarcoma.
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Analysis of 3 cohorts of human synovial sarcomas, comparing BSS to MSS tumors in each, 
identified very few genes with consistent differential expression (Fig. 7f). The most 
significant among these was the RAB3IP gene (Fig. 7g), which encodes one of only two 
proteins known to interact with SSX2 specifically. The interaction domain is not included in 
the portion of SSX2 fused to SS18 in the fusion oncoprotein.
Discussion
We report a new model of synovial sarcomagenesis in the mouse, driven by conditional 
expression of SS18-SSX1, complementing our former SS18-SSX2 model16. Exome 
sequencing demonstrated a striking absence of mutations that by allele fraction and gene 
transcription levels likely contributed to synovial sarcomagenesis. Although many mouse 
models of cancer demonstrate lower mutational burdens than their human counterparts, these 
mouse synovial sarcomas had particularly low mutation numbers per tumor28–34.
The only recurrent genetic change in tumors, beyond the activation of the hSS1 or hSS2 
fusion gene, was amplification of part or all of chromosome 6. Mouse tumors more 
frequently than human tumors demonstrate whole chromosome gains and losses35,36. While 
chromosome 6 trisomy may impact many genes, the partial chromosomal gains always 
included the Rosa26 locus and every copy number gain was an increase in the targeted 
allele. This indicates that increased expression of the fusion may contribute to oncogenesis. 
The increased expression by copy number gain is likely an artifact of expression from other 
than the native Ss18 locus. Indeed, the fact that one Ss18 allele is not disrupted by 
translocation may even emphasize the importance of increased expression of the fusion in 
the mice. The SS18-SSX fusion oncoprotein has been shown to compete with native SS18 
for participation in the SWI/SNF complex10. The mouse tumors must express enough of the 
fusion to out-compete two functional alleles of native Ss18.
These data suggest that mutations beyond activation and possible amplification of the fusion 
oncogene are not strictly necessary to enable synovial sarcomagenesis in the appropriate cell 
of origin in the mouse. Beyond the t(X;18) chromosomal translocation, additional genetic 
derangements that have been identified in a minority of human synovial sarcomas13,15 may 
contribute to tumor progression or make up for a less than ideal cell of origin.
Because SS18-SSX fusion oncogenes are capable of driving synovial sarcomagenesis 
independently, the details of each fusion genotype and differences between them might 
engender significant phenotypic differences in tumors. While a recent meta-analysis found 
no strong statistical justification for increased aggressiveness or worse prognosis in human 
SS18-SSX1 tumors25, our more detailed analysis of all the available human series confirmed 
that male hosts and BSS histology are specifically rare in the SS18-SSX2 genotype. In our 
direct comparison in mice, SS18-SSX2 was slightly more sarcomagenic than SS18-SSX1 
(and equal between genders) and generated BSS histology equivalently. Therefore, these 
represented two genotype-phenotype relationships in human synovial sarcoma that 
expression of each fusion in mice failed to recapitulate. Each demanded explanation.
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Each may derive purely from species differences between mouse and human. However, 
dismissal of these as species-specific modeling failures does not acknowledge one critical 
character of each departure. In the mouse, SS18-SSX2 drives more—not less—of synovial 
sarcoma biology than is apparent from human tumor epidemiology. In mice, there is no large 
subpopulation of males that do not develop tumors. There is no failure to develop the 
quintessential synovial sarcoma biology that reprograms mesenchymal cells to organize into 
the epithelial mucinous glandular structures of BSS histology. The model fails only to limit 
or partly block each of these biologies as is apparent in human SS18-SSX2 tumor 
epidemiology. Rather than species-specific differences in the response to each fusion 
genotype, therefore, it may relate instead to other artifacts of the model, particularly that 
expression of a cDNA of the fusion oncogene produced by a chromosomal translocation 
does not model the other genetic and epigenetic effects of the translocation on the genes near 
the translocated locus.
This alternate hypothesis that emphasizes the translocation locus effects was supported by 
the fact that SSX gene expression is almost the only differential expression between the two 
human tumor genotypes that is maintained across multiple patient series. It is also supported 
by the demonstration that human tumors almost universally express native SSX2 in addition 
to the fusion and that SS18-SSX1 tumors express more SSX2 than tumors of the SS18-
SSX2 fusion genotype. The fact that both tumorigenesis and BSS histology seem to be 
limited more profoundly in males also fits with an effect mediated by loss of native SSX2, 
on the X-chromosome.
Generally, X-linkage is considered only in germline heritable traits, due to inactivation of 
one X chromosome in each female somatic cell. Three points prompt its consideration in this 
somatic disorder: (1) The inactive X-chromosome in a female cell could be involved in the 
translocation itself. (2) Many genes on the inactive X chromosome in any female somatic 
cell are still expressed, escaping imprinting37. (3) The SSX genes are cancer/testis antigens, 
only expressed normally in the testis and remaining epigenetically silenced in all other cells 
unless pathologically activated in certain cancers7,8. Thus, whether residing on an active or 
inactive X chromosome, the SSX loci must be epigenetically reactivated to be expressed in a 
cancer arising outside the testis. A female cell will have two copies of each SSX locus 
physically available for such reactivation. Because SSX2B, a locus in opposite orientation 
but on the same arm of the X chromosome (Supplementary Fig. 3c), codes for the same 
protein as SSX2, female cells will have three copies and male cells will have one copy of the 
coding sequence available after the translocation that generates SS18-SSX2. The existence 
of SSX2B may explain the incomplete/subtle X-linkage of SSX2, evidenced by the non-zero 
prevalence of males with SS18-SSX2 tumors, generally, and even biphasic tumors in some 
series.
Demonstrating that modulation of SSX2 levels impacts proliferation in human synovial 
sarcoma cell lines suggests that SSX2 may function as an oncogene. Such a role has been 
demonstrated in other cancers, such as breast cancer, melanoma, and osteosarcoma38,39. 
Certainly, prospective experiments are warranted, as the capacity to generate translocations 
and assay transformation and tumorgenesis from them in normal human cells in vitro are 
developed.
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A role for native SSX2 in the de novo gland formation that is characteristic of BSS histology 
in synovial sarcomas will be even more difficult to test experimentally. Identification of 
RAB3IP as not only among, but most significant within the small group of genes 
differentially expressed consistently between three comparisons of BSS to MSS histology in 
human synovial sarcomas, was surprising. The SSX2 protein pulled down RAB3IP 
specifically in a yeast two-hybrid assay, whereas SSX1 did not40. The described interaction 
domain is in the portion of SSX2 not included in the fusion oncoprotein. A guanine 
exchange factor for RAB8, the protein encoded by the RAB3IP gene, often called Rabin8, 
has been shown to be important in gland initiation and ciliogenesis41–43. How SSX2 may 
impact these functions remains to be investigated once models are available.
We have therefore shown in mice that both SS18-SSX1 and SS18-SSX2 are capable of 
independently driving synovial sarcomagenesis. Insofar as these models test the impact of 
each fusion oncogene alone, we find no important tumor phenotypic differences. The 
differences we confirm epidemiologically in human tumors of the SS18-SSX2 translocation 
genotype we hypothesize to be related to the translocation locus rather than the fusion gene 
generated.
Materials and Methods
A Supplementary Detailed Methods section presents more specifics on each method utilized.
Study Design
Experimental designs were controlled laboratory experiments or depended on either data 
already collected or specimens already collected and previously reported and indicatedP. The 
only randomization employed was in manipulations applied to wells of cultured cells, which 
was done systematically, without any opportunity for bias. Individuals assessing outcomes of 
histology or cell counts were always blinded as to the group assignment of the specimen 
being analyzed. Sample size was not pre-calculated by power analysis as the inputs of 
sample variance were not known a priori for most experiments. For other experiments, there 
was a limited sample size available as subjects from the reported literature, such as in Table 
1. Series were excluded from that analysis if gender data or SS18-SSX genotype data was 
not reported and was not retrievable from the original corresponding authors. Otherwise, all 
data were included from each experiment reported. Outlier data points were not excluded 
from any analysis. Replicates for each cell line experiment are noted in the figure legends. 
Blinding was used for all assessments that included the potential for bias on the part of the 
assessor, such as histology and imaging.
Mice
All mouse work was performed with the approval of the institutional animal care and use 
committee and in accordance with international legal and ethical norms. The mice bearing 
Rosa26-targeted conditional SS18-SSX2, were previously described16, as were Rosa26-
CreER44, Myf5-Cre16 and Hprt-Cre45 mice. The full length cDNA of SS18-SSX1 was 
reverse transcribed from total RNA isolated from a human synovial sarcoma sample 
procured with approval of the institutional review board. Primers were identical to those 
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used for the prior isolation of SS18-SSX216. In all cases, mouse strains were maintained on 
a mixed C57BL/6 and SvJ background. Littermates were used for comparison controls, 
whenever possible. The sex of animals was equivalently male and female and not 
intentionally varied in any group.
Whole exome sequencing
Libraries were prepared using the Sure Select Mouse All Exon kit (Agilent Technologies) 
for exome enrichment. Paired-end (2×100bp) sequencing was performed with an Illumina 
HiSeq 2000 instrument. Reads were aligned to the UCSC mm9 mouse reference (derived 
from NCBI Mouse Build 37) with BWA (version 0.5.9 with parameters -t 4 -q 5). Tumor 
sample DNA sequencing was compared to paired germline control samples via a somatic 
variation pipeline using Samtools, Varscan, GATK and Pindel. IDT Targeted Sequencing 
was performed to validate somatic variants, with read coverage averaging 349.3±124.2.
Transcriptome sequencing
cDNA libraries were constructed using polyA for capture and sequenced on a 50bp single 
end read run on an Illumina HiSeq 2000 instrument. These were aligned onto UCSC mm9 
with CuffLinks software. Differential expression was calculated from read counts using 
DeSeq2 software.
Clinical Series
We retrieved the raw data from 17 of the largest clinical series of human synovial sarcomas 
in which the fusion type was identified by reverse transcriptase polymerase chain reaction 
(RT-PCR)20–24,46–57
With the approval of the institutional review board at the University of Utah and in 
accordance within all international legal and ethical standards, tissue samples from 
histologically and molecularly confirmed synovial sarcoma patients were procured after 
obtaining informed consent.
Expression Data
Raw data from Gene Expression Omnibus accession GSE20196 and GSE54187 were 
downloaded and analyzed using DChip software58.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Comparable synovial sarcomagenesis from SS18-SSX1 and SS18-SSX2
(a) Schematic of the derivation of both fusion oncogene transcripts SS18-SSX2 and SS18-
SSX1, showing the insertion of the latter into a Cre-loxP conditional expression vector at the 
Rosa26 locus. Cre-mediated recombination excises the stop sequence, enabling tandem 
expression of the fusion oncogene and the enhanced green fluorescent protein (eGFP) from 
an internal ribosomal entry site (IRES).
(b) Reverse transcriptase polymerase chain reaction (RT-PCR) with type-non-specific SS18-
SSX primers, showing expression 16 hours following administration of TATCre protein, but 
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not vehicle control, in both hSS2 and hSS1 mouse embryonic fibroblasts (MEFs) in vitro. 
Positive controls include the SS18-SSX2-expressing SYO1 and SS18-SSX1-expressing 
MoJo human synovial sarcoma cell lines.
(c) Fluorescence associated flow cytometry demonstrates increased apoptotic and dead cell 
fractions 72 hours following TATCre administration compared to controlled conditions in 
hSS1 and hSS2 MEFs in vitro.
(d) Most HprtCre-positive embryos heterozygous for hSS1 (middle) or hSS2 (lower) were 
already resorbed, but residual GFP+ tissue was retrieved at embryonic day 9.5 from one 
embryo each and compared to Cre-negative littermate controls (top).
(e) GFP fluorescence photos of tumors arising in hSS1 and hSS2 mice bearing Myf5Cre.
(f) Representative hematoxylin and eosin histopathology demonstrates monophasic fibrous 
(MSS, left) and biphasic glandular and fibrous (BSS, right) areas in human and mouse hSS1 
and hSS2 derived tumors. (Scale bars are 10 µm in length)
(g) Immunohistochemistry showing classic nuclear TLE1, cytoplasmic BCL2, and the 
typical, patchy epithelial membrane antigen (EMA) and pancytokeratin (AE1.3) staining in 
hSS1 derived tumors. (Scale bars are 10 µm in length)
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Figure 2. Whole exome sequencing of mouse synovial sarcomas demonstrates few mutations
(a) The variant allele fraction (VAF) for each mutation is plotted as upward deviation on the 
ordinate axis (scale to the left) plotted against the genomic location along the abscissa. Each 
of 16 Myf5-Cre;hSS1 tumor genomes is presented as a separate plot. (Brackets indicate 
which tumors arose in the same mouse.)
(b) List of the gene impacted and amino acid change associated with each mutation. (Cyan 
colored gene symbols indicate VAF ≥ 40).
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(c) Plot of the mean fold-change expression relative to Gapdh of the gene associated with 
each mutation across all the tumors (black column) as well as its expression in the mutation-
bearing (index) tumor (white column).
(d) Plot of the variant transcript frequency (VTF), or the fraction of mutated transcript reads 
over total transcripts reads that cross the mutation site in the index tumor.
(e) Mutations plotted for the genome of each of 13 Myf5-Cre;hSS2 tumors.
(f) Gene list for hSS2 tumor mutations. (Magenta colored gene symbols indicate VAF ≥ 40).
(g) Expression of genes involved by hSS2 tumor mutations.
(h) Fraction of mutated transcript reads in each index hSS2 tumor.
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Figure 3. Copy number analysis shows amplification of the fusion expression locus
(a) Plots of copy number variation for mouse chromosome 6 in 16 Myf5-Cre;hSS1 tumors 
relative to germline control DNA. (Arrows indicate the position of the Rosa26 locus in each 
tumor with partial amplification of chromosome 6.)
(b) Plots of copy number variation for mouse chromosome 6 in 13 Myf5-Cre;hSS2 tumors.
(c) Plot of the mean prevalence (±SD) of the PCR product of the targeted Rosa26 allele 
relative to the wildtype Rosa26 allele; the gain was in the targeted allele in all cases assessed 
(n = 8, p-value from Student’s t-test).
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Figure 4. Synovial sarcoma transcriptomes differ minimally by fusion genotype
(a) Heatmap of unsupervised hierarchical clustering of samples by FPKM values generated 
from sequencing of total RNA from tumors induced in mice by Myf5-Cre activation of 
either hSS1 (cyan) or hSS2 (magenta). Samples are listed as tumor numbers.
(b) Heatmap of unsupervised hierarchical clustering by FPKM of TATCre-induced tumors.
(c) Venn diagram of the genes 2-fold and significantly (p < 0.05) differentially expressed in 
14 hSS1 and 13 hSS2 tumors initiated by Myf5Cre, then 3 of each genotype initiated by 
TATCre injection into the hindlimb.
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(d) Unsupervised hierarchical clusterings of Myf5Cre-induced hSS1 and hSS2 tumors with 
heatmap demonstrating the log10 transformed FPKM expression values for genes selected 
by 2-fold and significant differential expression across both cohorts of mouse tumors by 
fusion type.
(e) Similar clustering with heatmap for the TATCre injection-induced tumors.
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Figure 5. Comparable sarcomagenesis between SS18-SSX1 and SS18-SSX2
(a) Plot of the non-morbid fraction of mice bearing Myf5-Cre (left) or Rosa26-CreER (right) 
and either hSS1 (n = 57 and 17) or hSS2 (n = 122 and 31) against age in days.
(b) Percentage of tumors in each anatomic location (tail, back, chest wall, hindlimb, 
forelimb, head, face) in mice of the Myf5-Cre (hSS1 n = 82, hSS2 n = 166) and Rosa26-
CreER (hSS1 n = 9, hSS2 n = 21) genotypes.
(c) Mean number of tumors per mouse among 41 Myf5-Cre;hSS1 and 48 Myf5Cre;hSS2 
mice with error bars demonstrating the standard deviations (p-value from Student’s t-test). 
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The mice of Rosa26-CreER genotypes had samples of 7 and 14, respectively for hSS1 and 
hSS2.
(d) The relative prevalence of BSS histology among all Myf5-Cre-induced tumors or the 
subset of tumors greater than 1 centimeter (samples of 41 total and 13 large hSS1 tumors 
and 123 total and 19 large hSS2 tumors, p-values represent two-tailed Fisher exact test). 
Also presented are the comparison of BSS fraction among tumors induced by Rosa26-
CreER (hSS1 n = 6, hSS2 n = 14) and TATCre (hSS1 n = 4, hSS2 n = 10).
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Figure 6. Human SS18-SSX1 and SS18-SSX2 synovial sarcomas differentially express SSX genes
(a) Venn diagram of differentially expressed genes (t-test p < 0.05) shared between 3 groups 
of human synovial sarcomas previously profiled by cDNA microarray.
(b) Cluster heatmap of one group of samples and all probes for the 7 genes differentially 
expressed in all three groups. (*indicates p-value < 0.5 differences between expression in the 
two tumor genotypes that was shared by the other samples in significance and direction of 
change.)
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(c) Gel image demonstrating RT-qPCR to determine the presence of each fusion gene in 23 
human synovial sarcoma samples, over the corresponding plot of RT-qPCR GAPDH-
normalized fold-change expression levels (relative to SSX1 in testis) of native SSX2 
(triangles) and SSX1 (circles), with cyan representing SS18-SSX1 tumors and magenta 
SS18-SSX2 tumors). Sample 9 demonstrated neither SS18-SSX1 nor SS18-SSX2 
expression. Sample 20 (annotated below with an additional male symbol), the only SS18-
SSX2 tumor from a male, was also the only tumor with negligible native SSX2 expression.
(d) Mean ± S.E.M. of the RT-qPCR-determined SSX2 expression for each human tumor 
fusion genotype. P-value is from two-tailed Student’s t-test.
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Figure 7. Possible roles for SSX2 in synovial sarcoma
(a) Mean ± SD GAPDH-normalized Western densitometry measurements of SSX2 
knockdown by three different siRNAs in human cell lines Fuji and Yamato, (exp. = 
expression; n = 3 biological replicates; experiment repeated).
(b) Mean fold-change ± SD in cell count 72 hours after application of siRNA (n = 3 
biological replicates; experiment repeated).
(c) Representative photomicrographs of cell density 72 hours after application of siRNA to 
the Fuji cell line (scale bars = 400 µm).
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(d) Westerns of SSX2 or its tag (DDX) 48 hours after transfection of an SSX2 
overexpression vector (CMV-SSX2), an SSX2 siRNA, or control conditions.
(e) Fold-changes in mean ± SD cell counts to measure proliferation 48 hours after 
transfection of an SSX2 overexpression vector (CMV-SSX2), an SSX2 siRNA, or control 
conditions. (* indicates two-tailed Student’s t-test p-value < 0.05; biological replicates per 
cell line: Fuji n = 5, MoJo n = 9, Yamato n = 6).
(f) Venn diagram of the numbers of unique genes differentially expressed to a significance of 
p<0.05 between biphasic and monophasic tumors in each group and shared between groups. 
Up arrows indicate genes relatively upregulated in biphasic tumors. Down arrows indicate 
genes relatively downregulated in biphasic tumors.
(g) Heatmap of microarray expression values of genes that were significantly upregulated in 
all three tumor cohorts, here presented in the GSE20196 cohort of SS18-SSX1-expressing 
tumors.
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Table 1
Testing for gender-specific prevalences of each fusion genotype in synovial sarcomagenesis.
Study
SS18-SSX1 SS18-SSX2
Male Female Male Female
Ladanyi, et al., 2002 73 72 31 56
Guillou, et al., 2004 61 51 19 34
Amary, et al., 2007 34 35 20 21
Sun, et al., 2009 32 18 47 44
Takenaka, et al., 2008 31 37 13 27
Ren, et al., 2013 27 20 29 12
Messelani, et al. 2001 21 19 7 17
Nakayama, et al., 2010 11 12 3 8
Fernebro, et al., 2006 8 4 5 4
Koković, et al., 2004 7 10 15 15
Inagaki, et al., 2000 6 4 2 7
Tvrdík, et al., 2005 4 1 0 2
Total 315 283 191 247
2×2 contingency: SS18-SSX1 SS18-SSX2 total
Male 315 191 506
Female 283 247 530
total 598 438 1036
Ratio 1.44
Fisher exact test p = 0.0046
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